Eli Lilly's investigational drug retatrutide showed significant reductions in blood sugar and weight loss in diabetes patients, outperforming placebo and rivaling Lilly’s Mounjaro. The notable weight loss of 15.3% at the highest dose could mark a substantial advancement for diabetes treatment, offering hope for more effective management of both blood sugar and obesity.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





